Sustained Release Oral Formulation For Treatment Of Parkinsons Disease

Trial statusNot yet recruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-65
SponsorUniversity of Minnesota

About this trial

LD/CD (medications to treat Parkinson's disease) will be delivered using an assembly of nested sachets made of permeable material. The assembly is placed in the oral/buccal cavity (between cheek and gum of lower jaw) and delivers continuous release of CD and LD for both transmucosal and gastrointestinal absorption. The combination of CD/LD in the inner sachet varies from that in the outer sachet. This allows for sequential release of CD and then LD to mimic a CD pretreatment method which is known to increase LD absorption and prolong its half-life.

Eligibility criteria

Qualifiers

Adult healthy male or female

Age 18 to 65 years

Willingness and ability to complete study procedures

Disqualifiers

medical conditions that require taking medications regularly.

Trial design

Treatments tested in this trial

  • Formulation A
  • Formulation B
  • Formulation C

Treatment groups

32 Participants
are divided into 3 treatment groups

Sponsors and collaborators